报价延迟最少15分钟:2026/09/04 00:11 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.58 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-10.00/-4.70
|
|
企业价值
21.78M
|
| 资产负债 |
|
每股账面净值
3.26
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.20M
|
|
每股收益
0.28
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs. |
